Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • JASN Podcasts
    • Article Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Editorial Fellowship
    • Editorial Fellowship Team
    • Editorial Fellowship Application Process
  • More
    • About JASN
    • Advertising
    • Alerts
    • Feedback
    • Impact Factor
    • Reprints
    • Subscriptions
  • ASN Kidney News
  • Other
    • ASN Publications
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • ASN Publications
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • JASN Podcasts
    • Article Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Editorial Fellowship
    • Editorial Fellowship Team
    • Editorial Fellowship Application Process
  • More
    • About JASN
    • Advertising
    • Alerts
    • Feedback
    • Impact Factor
    • Reprints
    • Subscriptions
  • ASN Kidney News
  • Follow JASN on Twitter
  • Visit ASN on Facebook
  • Follow JASN on RSS
  • Community Forum
UP FRONT MATTERSBrief Reviews
You have accessRestricted Access

New Insights into Nephrogenic Systemic Fibrosis

Sundararaman Swaminathan and Sudhir V. Shah
JASN October 2007, 18 (10) 2636-2643; DOI: https://doi.org/10.1681/ASN.2007060645
Sundararaman Swaminathan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sudhir V. Shah
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data Supps
  • Info & Metrics
  • View PDF
Loading

Abstract

Nephrogenic systemic fibrosis is a new disorder reported almost exclusively in patients who have renal insufficiency and are exposed to contrast media formulated with gadolinium. High morbidity and mortality are associated with this severely disabling and painful condition. The acute phase begins upon exposure to gadolinium contrast media, characterized by a systemic inflammatory response involving iron mobilization, and then as a progressive, chronic phase in which fibrosis develops. Proposed is a unifying model of cumulative risk factors in which the interplay of systemic inflammation and stimulated hematopoietic environment associated with hyperparathyroidism and erythropoietin may tie to a common pathogenic mechanism of fibrogenesis. Because there are no uniformly effective interventions to treat nephrogenic systemic fibrosis other than successful renal transplantation, prevention by avoiding gadolinium contrast media in patients with chronic kidney disease is vital. On the basis of suspected pathogenesis, it is also reasonable to limit erythropoietin and iron therapy to dosages ensuring recommended targets and adequately control hyperparathyroidism. Herein is reviewed what is currently known about this subject.

Nephrogenic systemic fibrosis (NSF) is a recently described systemic fibrosing disorder that has been reported almost exclusively in patients with renal insufficiency. It was first described by Cowper et al.1 in 2000 as a cutaneous scleromyxedema-like disorder in patients with ESRD and was initially called nephrogenic fibrosing dermopathy.2 Clinical and autopsy data now suggest the presence of a systemic fibrogenic reaction with evidence of involvement of muscle, tendons, diaphragm, testes, cardiac atrium, lungs, and duramater.3 The disease henceforth has been referred to as nephrogenic systemic fibrosis.4

More than 200 cases of NSF have been reported to the Food and Drug Administration and to the NSF registry at Yale University. The estimated prevalence of NSF, however, is likely to be inaccurate because it still is not a widely recognized clinical entity. In addition, subclinical forms of NSF that could be recognized only with a skin biopsy might remain undiagnosed. In this review, we describe novel clinical manifestations of NSF and discuss our views on its pathogenesis. Specifically, we present a general paradigm in which different risk factors may be tied to a common pathogenic mechanism.

CLINICAL AND LABORATORY FEATURES

NSF is a severely disabling systemic fibrosing condition associated with increased morbidity and mortality.5–7 Our observations suggest that clinical features of NSF may include an acute phase that immediately follows exposure to gadolinium-based contrast media (GBCM) and an overlapping chronic phase characterized by progressive fibrosis (Table 1). Features in the acute phase are variably present and mimic systemic inflammatory response syndrome: Fever, hypotension,acute kidney injury, anemia, leukoerythroblastic picture, thrombocytopenia or thrombocytosis, leukocytosis, eosinophilia, monocytosis, elevated γ-glutamyl peptidase, elevated lipase, and elevated D-dimer.8 Decreased total iron-binding capacity, elevated serum ferritin, low serum albumin, and elevated C-reactive protein are invariably present.7 Because many patients have critical illnesses such as sepsis, acute pancreatitis, hepatorenal syndrome, or acute graft dysfunction that precedes NSF, the acute phase of systemic fibrogenesis may go unrecognized. Onset of the chronic phase is also variable: As early as 4 d or as late as several months after GBCM exposure.9 Early cutaneous manifestations in the chronic phase are usually limited to generalized edema followed closely by the development of a plaque-like skin rash with woody induration (Figure 1A). The condition tends to affect either dependent parts of the body, such as extremities or the presacral area, or high blood-flow areas, such as the skin overlying an arteriovenous dialysis fistula.5,6 Facial involvement is very unusual except in severe, advanced cases in which temporal regions of the face may be involved (S. Swaminathan, 2006, personal observation). Moderate to severe pain is more typical. Alopecia, yellowish scleral nodules, hyperpigmentation of extremities, and yellowish discoloration of facial skin are observed in some patients. Additional systemic findings that have been observed in patients with NSF include the development of acute pancreatitis, vascular thrombosis, and frequent infection.5,10 The disease is severely disabling, and many patients become wheelchair dependent or bed bound. Severe depressive illness often ensues, and a significant number of patients quit dialysis.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

(A) NSF involving legs and hand. Note the induration, edema, plaque-like rash, and joint contractures. (B) Histopathologic appearance of NSF characterized by dermal spindle cell proliferation with extension into subcutaneous tissue.

View this table:
  • View inline
  • View popup
Table 1.

Components of NSF

The diagnosis of NSF is established by performing a deep-skin biopsy from affected areas. Biopsy findings (Figure 1B) that confirm NSF include dermal spindle cell (fibroblast) proliferation (usually CD34+) with frequent extension into subcutaneous tissue, presence of dermal mucin, variable infiltration of CD68+ macrophages, and presence of broad collagen bundles with clefts and fragmented elastin. Osseous metaplasia, osteoclast-like giant cells, and calciphylaxis can be seen in some NSF biopsies.11–13 On a technetium99-diphosphosphonate scan, areas of increased uptake can be observed in muscles.14,15 On magnetic resonance imaging, axial T1- and fat-suppressed T2-weighted images show symmetric skin thickening and soft tissue edema.15

The differential diagnoses of NSF include scleroderma, scleromyxedema, eosinophilic fasciitis, and graft-versus-host disease. An absence of facial involvement and circulating paraprotein, temporal relation to GBCM exposure, and the appropriate clinical context helps in differentiating NSF from these other conditions.

RISK FACTORS FOR NSF

The major risk factors associated with NSF include exposure to GBCM,9,16,17 high-dosage erythropoietin (EPO) therapy,7 elevated parathyroid hormone (PTH),7 hypothyroidism,17 and antiphospholipid antibodies.17 Significant vascular disease is also a risk factor.17 On the basis of current understanding, an interaction of low GFR; exposure to GBCM; and presence of additional risk factors such as high-dosage EPO, elevated PTH, vascular disease, and systemic inflammation seem necessary for the development of NSF in the majority of cases. In this “cumulative risk factor model” proposed by us and detailed in the following section, patients with more cumulative risk (risk factor load) may only need low dosages of GBCM to trigger NSF or vice versa (Figure 2).

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Cumulative risk factor model of NSF: Conceptual inverse interaction between gadolinium dosage and risk factors in the pathogenesis of NSF.

IMPAIRED RENAL FUNCTION

NSF is seen in patients both with acute kidney injury and with chronic kidney disease (CKD). No specific cause of kidney disease except hepatorenal syndrome15 has been associated with heightened risk. NSF is seen in patients receiving either hemodialysis or peritoneal dialysis as well as in patients with posttransplantation allograft dysfunction. Singularly, a low GFR is a major prerequisite for NSF to develop. In patients with CKD, on the basis of current reports as well as personal observations, the risk for NSF seems to be limited to those with stage 3 or worse CKD (GFR ≤60 ml/min). Recently, Sadowski et al. reported the risk for NSF after gadolinium exposure at various levels of estimated GFR (eGFR), and in their series, NSF developed predominantly in those with eGFR <30 ml/min.10 NSF also developed in two patients with an apparently higher eGFR in the setting of acute kidney injury, where formula-based estimates for GFR cannot be used. In our personal experience, we have observed, after GBCM exposure, that NSF can develop in patients with an eGFR as high as 40 ml/min. However, imprecision of formula-based eGFR in accurately predicting renal function in stage 3 CKD limits our ability to interpret these findings18 or arrive at a precise and safe cutoff of GFR above which the risk for NSF is negligible.

GADOLINIUM TOXICITY: ROLE OF IRON AND TRANSMETALLATION

In addition to several reports on the epidemiologic association of GBCM exposure and NSF, demonstration of gadolinium in NSF tissues has strengthened the causal link between the two.19 A higher dosage and multiple repeated exposures to GBCM increase the risk for NSF.10 The mechanisms through which administration of GBCM results in toxicity and NSF are still evolving. However, several important clues appear from current published literature. First, overt NSF develops in only 3 to 5% of patients after GBCM exposure.9,10,16 Second, some patients with NSF do not manifest any clinical signs, even when they were previously exposed to GBCM. Third, demonstration of significant quantities of insoluble gadolinium in the skin of patients with NSF, months after GBCM exposure and after extensive tissue processing, suggest that gadolinium might have undergone transmetallation in vivo. This finding is of significance because free gadolinium is toxic.20

Supporting the importance of transmetallation, all NSF cases reported thus far have been associated with linear magnetic resonance contrast agents9,16,21,22 that have inferior thermodynamic stability23–26 and a kinetic or conditional stability that favors transmetallation. The mechanism by which GBCM may undergo transmetallation in vivo or cause toxicity is still under investigation. In an initial report, acidosis was thought to induce gadolinium's dissociation from its chelate16; however, a subsequent report failed to confirm this.9 Administration of magnetic resonance contrast agents is widely known to cause transient (up to 72 h) elevations in serum iron, even in 15 to 30% of healthy volunteers.27,28 Because iron is tightly bound to ferritin and hemosiderin, it has been suggested that its free concentration is insufficient to induce transmetallation of GBCM25,29; however, we recently reported that GBCM administration in patients who have CKD and subsequently develop NSF results in a marked decrease in total iron-binding capacity, iron mobilization, profound transferrin oversaturation, and systemic inflammation.8 In patients with renal insufficiency, several factors may aggravate free iron release, including prolonged retention of GBCM (t½ 13.4 to 89.2 h versus 1.5 h controls),30 additional exogenous treatment with parenteral iron and low total iron-binding capacity secondary to malnutrition, urinary protein (transferrin) loss, sepsis, and chronic inflammation.31–33 Available data suggest that iron is most potent in inducing transmetallation of GBCM because the thermodynamic stability of Fe3+-DTPA-BMA (1021.9) far exceeds the thermodynamic stability constant of gadolinium-DTPA-BMA (1016.9)34 (Table 2).

View this table:
  • View inline
  • View popup
Table 2.

Potency of various endogenous cations in inducing transmetallation of gadolinium-DTPA-BMAa

Gadolinium-mobilized iron can also be directly toxic to tissues through the induction of oxidative stress by Fenton reaction (Figure 3).35 In addition, catalytic iron released by systemic inflammation35 and gadolinium-mediated cellular acquisition of catalytic iron might contribute to the development of NSF.35–38 Thus, a combination of free gadolinium, catalytic iron, systemic inflammation,10 and oxidative stress may result in initial injury and a subsequent systemic-fibrosing illness characteristic of NSF. Recent descriptions19,39 of significant iron and gadolinium deposition in NSF tissues support our findings. Collectively, these observations suggest the development of NSF after GBCM exposure needs not only a prolonged retention of GBCM but also a process by which GBCM induces toxicity, a process whereby iron may play an important role.

Figure 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3.

Transmetallation of gadolinium chelates by endogenous ions: The role of iron.

ROLE OF EPO, INFLAMMATION, AND VASCULAR INJURY

We and others7,17,40 recently reported that patients with NSF also receive higher dosages of EPO, suggesting that EPO might play a role in pathogenesis. On the basis of our clinical experience with 70 patients with NSF and other available large case series,7,8,17 it is uncommon that patients do not receive any EPO before NSF diagnosis. It is possible that endogenous EPO released during stress-induced erythropoiesis, which could be several hundred-fold,41 or other growth factors that synergize with EPO42 might be important in patients who do not receive exogenous EPO before a diagnosis of NSF. In addition, in applying the cumulative risk model (Figure 1), exogenous EPO may not be a necessary prerequisite in all cases.

There are many compelling reasons for why EPO might participate in the pathogenesis of NSF. Its pleiotropic biologic effects and/or systemic inflammation associated with an EPO-resistant state may be important (Table 3). Theoretically, EPO therapy influences all key elements of the pathogenesis of NSF: Endothelial dysfunction, inflammation, cell proliferation, and wound healing. EPO is a potent cytokine with stimulatory effects on vascular endothelium,43 smooth muscle cells,44,45 and platelets.46 EPO administration induces a release of vasoactive factors such as monocyte chemoattractant protein-1,45,47 endothelin-1,48 thromboxane A2, and selectin.46,49 It can also induce endothelial dysfunction by inhibiting dimethylarginine dimethylaminohydrolase, thereby increasing asymmetric dimethyl arginine.50 Furthermore, EPO is a potent stimulant of endothelial and progenitor cell proliferation,51,52 as well as wound-healing responses53 that are reminiscent of histologic changes seen in NSF. EPO51,52,54 and PTH55 are also strong stimuli for a systemic release of CD34+ progenitor cells, which are known to participate in wound healing.56–58 Vascular endothelial cell injury could similarly contribute to the pathogenesis of NSF by inducing the release of vasoactive factors and CD34+ progenitors,41,59 and in this setting, EPO's detrimental effect on endothelia is further aggravated.60,61 In addition, chronic inflammation62 associated with an EPO-resistant state and high-dosage EPO45,47 might also contribute to the fibrogenesis seen in NSF.

View this table:
  • View inline
  • View popup
Table 3.

Potential role of EPO in the pathogenesis of NSF

CELLULAR BASIS FOR THE PERSISTENCE OF FIBROSIS IN NSF

As with any other systemic fibrosing condition,63 possible origins of fibroblasts in NSF include resident mesenchymal cell populations, epithelial-to-mesenchymal transition of local epithelia, and bone marrow–derived cells. Cowper and Bucala64 demonstrated that the spindle cells in NSF skin lesions express CD34 and procollagen 1 and suggested that circulating fibrocytes mediate the fibrosis in NSF. Even though the presence of these markers suggests a contribution from circulating fibrocytes, it is important to note that these markers are not unique to fibrocytes65; fibrocyte's contribution to fibrosis is highly variable in different organs66 and is affected by additional factors such as cell turnover rates. Supporting this, Fathke et al.,67 using cross-transplantation (bone marrow) experiments in an EGFP transgenic mouse model, nicely demonstrated that both CD45+ and CD45− bone marrow–derived stem cells contribute to dermal collagen deposition and wound repair. In addition, they observed a role for local dermal cells and endothelial progenitor cells in dermal wound healing. Similarly, using tissue reconstitution experiments with single hematopoietic stem cells (HSC), Ogawa et al.56 showed that HSC significantly contribute to myofibroblast population in tissues. EPO, PTH, and an oxidative stress-induced “stimulated hematopoietic environment”41,51,55,68,69 may thus contribute to fibrosis through increased production of tissue myofibroblasts. It is unknown, however, whether fibrocytes are a necessary intermediate in this process of transformation of HSC into myofibroblasts in vivo; therefore, it is likely that both resident fibroblasts and diverse types of bone marrow–derived cells that are released in response to injury and cytokines such as EPO, including HSC (likely to be the most significant contributor), endothelial progenitor cells, mesenchymal precursors,65 and monocyte-derived cell fibrocytes,64 contribute to fibrogenesis in NSF (Figure 4). Any contribution of epithelial-to-mesenchymal transition to fibrogenesis in NSF, although potentially possible, has not been evaluated. Like other chronic fibrosing disorders, persistent or progressive fibrosis, even after the original trigger is removed, may lead to NSF. This occurrence possibly relates to the concept of a “persistently activated fibroblast phenotype,” which could be mediated by factors such as ongoing chronic endothelial injury in uremia.70,71

Figure 4.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 4.

Cellular basis for fibrosis in NSF: Interaction of multiple risk factors and central role of hematopoietic stem cells.

TREATMENT

There are no good therapies for the cutaneous symptoms of NSF or, more important, to prevent its associated high mortality; therefore, our first recommendation is prevention. On the basis of the available data and our personal experience, we recommend the following measures for NSF prevention:

Renal function should be checked in all high-risk patients before GBCM administration (age >50 yr; infants; history of renal disease, diabetes, hypertension, or liver disease; and critically ill patients).

Avoid GBCM in patients with an eGFR <40 ml/min.

If clinically indicated and benefits outweigh risks, then use low dosages of GBCM (preferably macrocyclic agents) in patients with an eGFR of 40 to 60 ml/min.

GBCM is absolutely contraindicated in patients who are on peritoneal dialysis, because gadolinium is poorly cleared by the peritoneum.

In patients who are on hemodialysis, GBCM should be administered only if the benefits of obtaining a contrast-enhanced magnetic resonance image substantially outweigh the risk. At the completion of imaging, patients should go directly to the hemodialysis unit for initiation of dialysis, and dialysis treatment should be administered for 3 consecutive days.

Avoid intravenous iron immediately before or after GBCM exposure.

Treatment of NSF involves a multidisciplinary approach. Aggressive physical therapy, pain control, and psychologic support are essential cornerstones of therapy in this severely disabling disease. The severity of pain usually necessitates opiate analgesics. Topical treatments include the use of moisturizers, emollients, and anti-inflammatory creams. Deep tissue massage and hydrotherapy may be helpful. On the basis of potential pathogenic mechanisms, control of PTH levels and limiting administration of EPO and intravenous iron enough to maintain recommended hemoglobin targets are likely to help. Limiting systemic inflammation by decreasing infection episodes such as catheter-related bacteremia may also be beneficial. Other treatment approaches that could result in variable and modest improvements include a combination of hydroxychloroquine and low-dosage steroids (S. Swaminathan, 2006, personal observation), extracorporeal photopheresis, and topical ultraviolet-A therapy. However, none of these options has been uniformly effective in patients with NSF. Renal transplantation that results in a well-functioning allograft usually leads to a substantial resolution of the disease, and maintaining lower cyclosporine and tacrolimus targets may also potentially help in limiting fibrogenesis.72–74 Secondary worsening of NSF after initial improvement but without new GBCM exposure can occur, but the mechanisms involved in these relapses are unclear. No data are available on the benefit of using chelation therapy to remove gadolinium in NSF. A better understanding of the pathogenesis in this devastating disease may lead to new interventions, which may be relevant not only to NSF but other fibrosing conditions.

Disclosures

None.

Acknowledgments

We thank Cindy Reid for technical editing and graphics assistance.

Footnotes

  • Published online ahead of print. Publication date available at www.jasn.org.

  • © 2007 American Society of Nephrology

References

  1. ↵
    Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, LeBoit PE: Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 356 : 1000 –1001, 2000
    OpenUrlCrossRefPubMed
  2. ↵
    Cowper SE, Su LD, Bhawan J, Robin HS, LeBoit PE: Nephrogenic fibrosing dermopathy. Am J Dermatopathol 23 : 383 –393, 2001
    OpenUrlCrossRefPubMed
  3. ↵
    Ting WW, Stone MS, Madison KC, Kurtz K: Nephrogenic fibrosing dermopathy with systemic involvement. Arch Dermatol 139 : 903 –906, 2003
    OpenUrlCrossRefPubMed
  4. ↵
    Cowper SE: Nephrogenic systemic fibrosis: The nosological and conceptual evolution of nephrogenic fibrosing dermopathy. Am J Kidney Dis 46 : 763 –765, 2005
    OpenUrlCrossRefPubMed
  5. ↵
    Cowper SE: Nephrogenic fibrosing dermopathy: The first 6 years. Curr Opin Rheumatol 15 : 785 –790, 2003
    OpenUrlCrossRefPubMed
  6. ↵
    Swaminathan S, Leung N: Nephrogenic fibrosing dermopathy: Lessons from the past. Int J Dermatol 45 : 639 –641, 2006
    OpenUrlCrossRefPubMed
  7. ↵
    Swaminathan S, Ahmed I, McCarthy JT, Albright RC, Pittelkow MR, Caplice NM, Griffin MD, Leung N: Nephrogenic fibrosing dermopathy and high-dose erythropoietin therapy. Ann Intern Med 145 : 234 –235, 2006
    OpenUrlCrossRefPubMed
  8. ↵
    Swaminathan S, Horn TD, Pellowski D, Abul-Ezz S, Bornhorst JA, Viswamitra S, Shah SV: Nephrogenic systemic fibrosis, gadolinium, and iron mobilization. N Engl J Med 357 : 720 –722, 2007
    OpenUrlCrossRefPubMed
  9. ↵
    Marckmann P, Skov L, Rossen K, Dupont A, Damholt MB, Heaf JG, Thomsen HS: Nephrogenic systemic fibrosis: Suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 17 : 2359 –2362, 2006
    OpenUrlAbstract/FREE Full Text
  10. ↵
    Sadowski EA, Bennett LK, Chan MR, Wentland AL, Garrett AL, Garrett RW, Djamali A: Nephrogenic systemic fibrosis: Risk factors and incidence estimation. Radiology 243 : 148 –157, 2007
    OpenUrlCrossRefPubMed
  11. ↵
    Ruiz-Genao DP, Pascual-Lopez MP, Fraga S, Aragues M, Garcia-Diez A: Osseous metaplasia in the setting of nephrogenic fibrosing dermopathy. J Cutan Pathol 32 : 172 –175, 2005
    OpenUrlCrossRefPubMed
  12. Hershko K, Hull C, Ettefagh L, Nedorost S, Dyson S, Horn T, Gilliam AC: A variant of nephrogenic fibrosing dermopathy with osteoclast-like giant cells: A syndrome of dysregulated matrix remodeling? J Cutan Pathol 31 : 262 –265, 2004
    OpenUrlCrossRefPubMed
  13. ↵
    Edsall LC, English JC 3rd, Teague MW, Patterson JW: Calciphylaxis and metastatic calcification associated with nephrogenic fibrosing dermopathy. J Cutan Pathol 31 : 247 –253, 2004
    OpenUrlCrossRefPubMed
  14. ↵
    Gremmels JM, Kirk GA: Two patients with abnormal skeletal muscle uptake of Tc-99m hydroxymethylene diphosphonate following liver transplant: Nephrogenic fibrosing dermopathy and graft vs host disease. Clin Nucl Med 29 : 694 –697, 2004
    OpenUrlCrossRefPubMed
  15. ↵
    Broome DR, Girguis MS, Baron PW, Cottrell AC, Kjellin I, Kirk GA: Gadodiamide-associated nephrogenic systemic fibrosis: Why radiologists should be concerned. AJR Am J Roentgenol 188 : 586 –592, 2007
    OpenUrlCrossRefPubMed
  16. ↵
    Grobner T: Gadolinium: A specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 21 : 1104 –1108, 2006
    OpenUrlCrossRefPubMed
  17. ↵
    Nephrogenic fibrosing dermopathy associated with exposure to gadolinium-containing contrast agents—St. Louis, Missouri, 2002–2006. MMWR Morb Mortal Wkly Rep 56 : 137 –141, 2007
    OpenUrlPubMed
  18. ↵
    Poggio ED, Wang X, Greene T, Van Lente F, Hall PM: Performance of the modification of diet in renal disease and Cockcroft-Gault equations in the estimation of GFR in health and in chronic kidney disease. J Am Soc Nephrol 16 : 459 –466, 2005
    OpenUrlAbstract/FREE Full Text
  19. ↵
    High WA, Ayers RA, Cowper SE: Gadolinium is quantifiable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 56 : 710 –712, 2007
    OpenUrlCrossRefPubMed
  20. ↵
    Spencer AJ, Wilson SA, Batchelor J, Reid A, Rees J, Harpur E: Gadolinium chloride toxicity in the rat. Toxicol Pathol 25 : 245 –255, 1997
    OpenUrlCrossRefPubMed
  21. ↵
    Thomsen HS, Morcos SK, Dawson P: Is there a causal relation between the administration of gadolinium based contrast media and the development of nephrogenic systemic fibrosis (NSF)? Clin Radiol 61 : 905 –906, 2006
    OpenUrlCrossRefPubMed
  22. ↵
    Thomsen HS: Nephrogenic systemic fibrosis: A serious late adverse reaction to gadodiamide. Eur Radiol 16 : 2619 –2621, 2006
    OpenUrlCrossRefPubMed
  23. ↵
    Puttagunta NR, Gibby WA, Smith GT: Human in vivo comparative study of zinc and copper transmetallation after administration of magnetic resonance imaging contrast agents. Invest Radiol 31 : 739 –742, 1996
    OpenUrlCrossRefPubMed
  24. Puttagunta NR, Gibby WA, Puttagunta VL: Comparative transmetallation kinetics and thermodynamic stability of gadolinium-DTPA bis-glucosamide and other magnetic resonance imaging contrast media. Invest Radiol 31 : 619 –624, 1996
    OpenUrlCrossRefPubMed
  25. ↵
    Mann JS: Stability of gadolinium complexes in vitro and in vivo. J Comput Assist Tomogr 17[Suppl 1] : S19 –S23, 1993
    OpenUrl
  26. ↵
    Kirchin MA, Runge VM: Contrast agents for magnetic resonance imaging: Safety update. Top Magn Reson Imaging 14 : 426 –435, 2003
    OpenUrlCrossRefPubMed
  27. ↵
    VanWagoner M, O’Toole M, Worah D, Leese PT, Quay SC: A phase I clinical trial with gadodiamide injection, a nonionic magnetic resonance imaging enhancement agent. Invest Radiol 26 : 980 –986, 1991
    OpenUrlPubMed
  28. ↵
    Shellock FG, Kanal E: Safety of magnetic resonance imaging contrast agents. J Magn Reson Imaging 10 : 477 –484, 1999
    OpenUrlCrossRefPubMed
  29. ↵
    Cacheris WP, Quay SC, Rocklage SM: The relationship between thermodynamics and the toxicity of gadolinium complexes. Magn Reson Imaging 8 : 467 –481, 1990
    OpenUrlCrossRefPubMed
  30. ↵
    Joffe P, Thomsen HS, Meusel M: Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Acad Radiol 5 : 491 –502, 1998
    OpenUrlCrossRefPubMed
  31. ↵
    Pupim LB, Caglar K, Hakim RM, Shyr Y, Ikizler TA: Uremic malnutrition is a predictor of death independent of inflammatory status. Kidney Int 66 : 2054 –2060, 2004
    OpenUrlCrossRefPubMed
  32. Kaysen GA, Eiserich JP: Characteristics and effects of inflammation in end-stage renal disease. Semin Dial 16 : 438 –446, 2003
    OpenUrlCrossRefPubMed
  33. ↵
    Pupim LB, Evanson JA, Hakim RM, Ikizler TA: The extent of uremic malnutrition at the time of initiation of maintenance hemodialysis is associated with subsequent hospitalization. J Ren Nutr 13 : 259 –266, 2003
    OpenUrlCrossRefPubMed
  34. ↵
    Idee JM, Port M, Raynal I, Schaefer M, Le Greneur S, Corot C: Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: A review. Fundam Clin Pharmacol 20 : 563 –576, 2006
    OpenUrlCrossRefPubMed
  35. ↵
    Shah SV, Alam MG: Role of iron in atherosclerosis. Am J Kidney Dis 41 : S80 –S83, 2003
    OpenUrlCrossRefPubMed
  36. Olakanmi O, Stokes JB, Pathan S, Britigan BE: Polyvalent cationic metals induce the rate of transferrin-independent iron acquisition by HL-60 cells. J Biol Chem 272 : 2599 –2606, 1997
    OpenUrlAbstract/FREE Full Text
  37. Olakanmi O, Stokes JB, Britigan BE: Gallium-inducible transferrin-independent iron acquisition is a property of many cell types: Possible role of alterations in the plasma membrane. J Investig Med 53 : 143 –153, 2005
    OpenUrlCrossRefPubMed
  38. ↵
    Olakanmi O, Rasmussen GT, Lewis TS, Stokes JB, Kemp JD, Britigan BE: Multivalent metal-induced iron acquisition from transferrin and lactoferrin by myeloid cells. J Immunol 169 : 2076 –2084, 2002
    OpenUrlAbstract/FREE Full Text
  39. High WA, Ayers RA, Chandler J, Zito G, Cowper SE: Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 56 : 21 –26, 2007
    OpenUrlCrossRefPubMed
  40. ↵
    Marckmann P, Skov L, Rossen K, Heaf JG, Thomsen HS: Case-control study of gadodiamide-related nephrogenic systemic fibrosis. Nephrol Dial Transplant 17 : 2359 –2362, 2007
    OpenUrl
  41. ↵
    Socolovsky M: Molecular insights into stress erythropoiesis. Curr Opin Hematol 14 : 215 –224, 2007
    OpenUrlCrossRefPubMed
  42. ↵
    Sigounas G, Steiner M, Anagnostou A: Synergism of hemopoietic growth factors on endothelial cell proliferation. Angiology 48 : 141 –147, 1997
    OpenUrlPubMed
  43. ↵
    Anagnostou A, Lee ES, Kessimian N, Levinson R, Steiner M: Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc Natl Acad Sci U S A 87 : 5978 –5982, 1990
    OpenUrlAbstract/FREE Full Text
  44. ↵
    Ammarguellat F, Llovera M, Kelly PA, Goffin V: Low doses of EPO activate MAP kinases but not JAK2-STAT5 in rat vascular smooth muscle cells. Biochem Biophys Res Commun 284 : 1031 –1038, 2001
    OpenUrlCrossRefPubMed
  45. ↵
    Desai A, Zhao Y, Lankford HA, Warren JS: Nitric oxide suppresses EPO-induced monocyte chemoattractant protein-1 in endothelial cells: Implications for atherogenesis in chronic renal disease. Lab Invest 86 : 369 –379, 2006
    OpenUrlCrossRefPubMed
  46. ↵
    Stohlawetz PJ, Dzirlo L, Hergovich N, Lackner E, Mensik C, Eichler HG, Kabrna E, Geissler K, Jilma B: Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans. Blood 95 : 2983 –2989, 2000
    OpenUrlAbstract/FREE Full Text
  47. ↵
    De Marchi S, Cecchin E, Falleti E, Giacomello R, Stel G, Sepiacci G, Bortolotti N, Zanello F, Gonano F, Bartoli E: Long-term effects of erythropoietin therapy on fistula stenosis and plasma concentrations of PDGF and MCP-1 in hemodialysis patients. J Am Soc Nephrol 8 : 1147 –1156, 1997
    OpenUrlAbstract
  48. ↵
    Carlini RG, Dusso AS, Obialo CI, Alvarez UM, Rothstein M: Recombinant human erythropoietin (rHuEPO) increases endothelin-1 release by endothelial cells. Kidney Int 43 : 1010 –1014, 1993
    OpenUrlCrossRefPubMed
  49. Kahraman S, Yilmaz R, Kirkpantur A, Genctoy G, Arici M, Altun B, Erdem Y, Yasavul U, Turgan C: Impact of rHuEPO therapy initiation on soluble adhesion molecule levels in haemodialysis patients. Nephrology (Carlton) 10 : 264 –269, 2005
    OpenUrlCrossRefPubMed
  50. ↵
    Scalera F, Kielstein JT, Martens-Lobenhoffer J, Postel SC, Tager M, Bode-Boger SM: Erythropoietin increases asymmetric dimethylarginine in endothelial cells: Role of dimethylarginine dimethylaminohydrolase. J Am Soc Nephrol 16 : 892 –898, 2005
    OpenUrlAbstract/FREE Full Text
  51. ↵
    Bahlmann FH, DeGroot K, Duckert T, Niemczyk E, Bahlmann E, Boehm SM, Haller H, Fliser D: Endothelial progenitor cell proliferation and differentiation is regulated by erythropoietin. Kidney Int 64 : 1648 –1652, 2003
    OpenUrlCrossRefPubMed
  52. ↵
    George J, Goldstein E, Abashidze A, Wexler D, Hamed S, Shmilovich H, Deutsch V, Miller H, Keren G, Roth A: Erythropoietin promotes endothelial progenitor cell proliferative and adhesive properties in a PI 3-kinase-dependent manner. Cardiovasc Res 68 : 299 –306, 2005
    OpenUrlCrossRefPubMed
  53. ↵
    Galeano M, Altavilla D, Bitto A, Minutoli L, Calo M, Lo Cascio P, Polito F, Giugliano G, Squadrito G, Mioni C, Giuliani D, Venuti FS, Squadrito F: Recombinant human erythropoietin improves angiogenesis and wound healing in experimental burn wounds. Crit Care Med 34 : 1139 –1146, 2006
    OpenUrlCrossRefPubMed
  54. ↵
    Heeschen C, Aicher A, Lehmann R, Fichtlscherer S, Vasa M, Urbich C, Mildner-Rihm C, Martin H, Zeiher AM, Dimmeler S: Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood 102 : 1340 –1346, 2003
    OpenUrlAbstract/FREE Full Text
  55. ↵
    Ballen K: Targeting the stem cell niche: Squeezing blood from bones. Bone Marrow Transplant 39 : 655 –660, 2007
    OpenUrlCrossRefPubMed
  56. ↵
    Ogawa M, LaRue AC, Drake CJ: Hematopoietic origin of fibroblasts/myofibroblasts: Its pathophysiologic implications. Blood 108 : 2893 –2896, 2006
    OpenUrlAbstract/FREE Full Text
  57. Haroon ZA, Amin K, Jiang X, Arcasoy MO: A novel role for erythropoietin during fibrin-induced wound-healing response. Am J Pathol 163 : 993 –1000, 2003
    OpenUrlCrossRefPubMed
  58. ↵
    Sayan H, Ozacmak VH, Guven A, Aktas RG, Ozacmak ID: Erythropoietin stimulates wound healing and angiogenesis in mice. J Invest Surg 19 : 163 –173, 2006
    OpenUrlCrossRefPubMed
  59. ↵
    Wojakowski W, Tendera M, Michalowska A, Majka M, Kucia M, Maslankiewicz K, Wyderka R, Ochala A, Ratajczak MZ: Mobilization of CD34/CXCR4+, CD34/CD117+, c-met+ stem cells, and mononuclear cells expressing early cardiac, muscle, and endothelial markers into peripheral blood in patients with acute myocardial infarction. Circulation 110 : 3213 –3220, 2004
    OpenUrlAbstract/FREE Full Text
  60. ↵
    Ando M, Iwata A, Ozeki Y, Tsuchiya K, Akiba T, Nihei H: Circulating platelet-derived microparticles with procoagulant activity may be a potential cause of thrombosis in uremic patients. Kidney Int 62 : 1757 –1763, 2002
    OpenUrlCrossRefPubMed
  61. ↵
    Coleman TR, Westenfelder C, Togel FE, Yang Y, Hu Z, Swenson L, Leuvenink HG, Ploeg RJ, d’Uscio, LV, Katusic ZS, Ghezzi P, Zanetti A, Kaushansky K, Fox NE, Cerami A, Brines M: Cytoprotective doses of erythropoietin or carbamylated erythropoietin have markedly different procoagulant and vasoactive activities. Proc Natl Acad Sci U S A 103 : 5965 –5970, 2006
    OpenUrlAbstract/FREE Full Text
  62. ↵
    Meneghin A, Hogaboam CM: Infectious disease, the innate immune response, and fibrosis. J Clin Invest 117 : 530 –538, 2007
    OpenUrlCrossRefPubMed
  63. ↵
    Wynn TA: Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J Clin Invest 117 : 524 –529, 2007
    OpenUrlCrossRefPubMed
  64. ↵
    Cowper SE, Bucala R: Nephrogenic fibrosing dermopathy: Suspect identified, motive unclear. Am J Dermatopathol 25 : 358 , 2003
    OpenUrlCrossRefPubMed
  65. ↵
    Kuwana M, Okazaki Y, Kodama H, Izumi K, Yasuoka H, Ogawa Y, Kawakami Y, Ikeda Y: Human circulating CD14+ monocytes as a source of progenitors that exhibit mesenchymal cell differentiation. J Leukoc Biol 74 : 833 –845, 2003
    OpenUrlCrossRefPubMed
  66. ↵
    Iredale JP: Models of liver fibrosis: Exploring the dynamic nature of inflammation and repair in a solid organ. J Clin Invest 117 : 539 –548, 2007
    OpenUrlCrossRefPubMed
  67. ↵
    Fathke C, Wilson L, Hutter J, Kapoor V, Smith A, Hocking A, Isik F: Contribution of bone marrow-derived cells to skin: Collagen deposition and wound repair. Stem Cells 22 : 812 –822, 2004
    OpenUrlCrossRefPubMed
  68. ↵
    Calvi LM, Adams GB, Weibrecht KW, Weber JM, Olson DP, Knight MC, Martin RP, Schipani E, Divieti P, Bringhurst FR, Milner LA, Kronenberg HM, Scadden DT: Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 425 : 841 –846, 2003
    OpenUrlCrossRefPubMed
  69. ↵
    Liu J, Finkel T: Stem cell aging: What bleach can teach. Nat Med 12 : 383 –384, 2006
    OpenUrlCrossRefPubMed
  70. ↵
    Dou L, Bertrand E, Cerini C, Faure V, Sampol J, Vanholder R, Berland Y, Brunet P: The uremic solutes p-cresol and indoxyl sulfate inhibit endothelial proliferation and wound repair. Kidney Int 65 : 442 –451, 2004
    OpenUrlCrossRefPubMed
  71. ↵
    Laplante P, Raymond MA, Gagnon G, Vigneault N, Sasseville AM, Langelier Y, Bernard M, Raymond Y, Hebert MJ: Novel fibrogenic pathways are activated in response to endothelial apoptosis: Implications in the pathophysiology of systemic sclerosis. J Immunol 174 : 5740 –5749, 2005
    OpenUrlAbstract/FREE Full Text
  72. ↵
    McMorrow T, Gaffney MM, Slattery C, Campbell E, Ryan MP: Cyclosporine A induced epithelial-mesenchymal transition in human renal proximal tubular epithelial cells. Nephrol Dial Transplant 20 : 2215 –2225, 2005
    OpenUrlCrossRefPubMed
  73. Ceol M, Anglani F, Vianello D, Murer L, Del Prete D, Forino M, Favaro S, Gambaro G, D’Angelo A: Direct effect of chronic cyclosporine treatment on collagen III mRNA expression and deposition in rat kidneys. Clin Nephrol 53[Suppl 8–9] , 2000
  74. ↵
    Johnson DW, Saunders HJ, Johnson FJ, Huq SO, Field MJ, Pollock CA: Fibrogenic effects of cyclosporin A on the tubulointerstitium: Role of cytokines and growth factors. Exp Nephrol 7 : 470 –478, 1999
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Journal of the American Society of Nephrology: 18 (10)
Journal of the American Society of Nephrology
Vol. 18, Issue 10
October 2007
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in JASN.
Enter multiple addresses on separate lines or separate them with commas.
New Insights into Nephrogenic Systemic Fibrosis
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
New Insights into Nephrogenic Systemic Fibrosis
Sundararaman Swaminathan, Sudhir V. Shah
JASN Oct 2007, 18 (10) 2636-2643; DOI: 10.1681/ASN.2007060645

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
New Insights into Nephrogenic Systemic Fibrosis
Sundararaman Swaminathan, Sudhir V. Shah
JASN Oct 2007, 18 (10) 2636-2643; DOI: 10.1681/ASN.2007060645
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Abstract
    • CLINICAL AND LABORATORY FEATURES
    • RISK FACTORS FOR NSF
    • IMPAIRED RENAL FUNCTION
    • GADOLINIUM TOXICITY: ROLE OF IRON AND TRANSMETALLATION
    • ROLE OF EPO, INFLAMMATION, AND VASCULAR INJURY
    • CELLULAR BASIS FOR THE PERSISTENCE OF FIBROSIS IN NSF
    • TREATMENT
    • Disclosures
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data Supps
  • Info & Metrics
  • View PDF

More in this TOC Section

UP FRONT MATTERS

  • Predicting Future Outcomes from Kidney Biopsies with MCD/FSGS Lesions: Opportunities and Limitations
  • Autoimmune Renal Calcium and Magnesium Wasting
  • Kidney Health Disparities: The Goal is Elimination
Show more UP FRONT MATTERS

Brief Reviews

  • Differentiating Primary, Genetic, and Secondary FSGS in Adults: A Clinicopathologic Approach
  • Salt-Losing Tubulopathies in Children: What’s New, What’s Controversial?
  • Targeting B Cells and Plasma Cells in Glomerular Diseases: Translational Perspectives
Show more Brief Reviews

Cited By...

  • The Gut Microbiome in Intestinal Fibrosis: Environmental Protector or Provocateur?
  • Low Risk for Nephrogenic Systemic Fibrosis in Nondialysis Patients Who Have Chronic Kidney Disease and Are Investigated with Gadolinium-Enhanced Magnetic Resonance Imaging
  • Management of Symptomatic Carotid Stenosis in Individuals with CKD
  • Measured GFR as a Confirmatory Test for Estimated GFR
  • Nephrogenic Systemic Fibrosis: Pathogenesis, Diagnosis, and Therapy
  • Ultrastructural Evidence of Dermal Gadolinium Deposits in a Patient with Nephrogenic Systemic Fibrosis and End-Stage Renal Disease
  • Renal impairment
  • Google Scholar

Similar Articles

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Annual Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Author Resources
  • Editorial Fellowship Program
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • JASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About JASN
  • JASN Email Alerts
  • JASN Key Impact Information
  • JASN Podcasts
  • JASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe to ASN Journals

© 2022 American Society of Nephrology

Print ISSN - 1046-6673 Online ISSN - 1533-3450

Powered by HighWire